Author

A. Prosz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Organism:human· 3 Approach:statistical model· 3 Research Focus:differential expression· 2 Assay:whole-exome sequencing· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

P. Sahgal· 3 shared S. Spisak· 3 shared V. Tisza· 3 shared Z. Szallasi· 3 shared Z. Sztupinszki· 3 shared H. Singh· 2 shared I. Csabai· 2 shared J. M. Cleary· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

P. Sahgal

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Replicative stress in gastroesophageal adenocarcinoma is associated with chromosomal instability and sensitivity to DNA damage response inhibitors.

P. Sahgal, D. T. Patil, Z. Sztupinszki, V. Tisza, S. Spisak, B. Huffman, A. Prosz, H. Singh, J.-B. Lazaro, Z. Szallasi, J. M. Cleary, N. S. Sethi

The paper identifies DDR biomarkers and ploidy abnormalities in GEA that predict sensitivity to DDR inhibitors and premalignant progression.

bioRxiv · Mar 27, 2023 · PreprintCancer Biology

Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma.

A. Prosz, H. Duan, V. Tisza, P. Sahgal, S. Topka, G. T.Klus, J. Borscok, Z. Sztupinszki, T. Hanlon, M. Diossy, L. Vizkeleti, D. R. Stormoen, I. Csabai, H. Pappot, J. Vijai, , Z. Szallasi

This paper identifies NER deficiency as a targetable vulnerability in ccRCC, showing that 10% of patients may respond to irofulven based on mutational signatures and PTGR1 expression.

bioRxiv · Feb 7, 2023Cancer Biology

Diagnostic tool to identify and treat DNA repair deficient gastroesophageal adenocarcinomas

A. Prosz, P. Sahgal, C. X. Morris, Z. Sztupinszki, J. Borcsok, M. Diossy, V. Tisza, S. Spisak, O. Rusz, I. Csabai, B. M. Huffman, H. Singh, J.-B. Lazaro, M. Cecchini, J. M. Cleary, , N. S. Sethi

This study identifies HR and NER deficiencies in gastric and esophageal adenocarcinomas and shows their responsiveness to platinum chemotherapy and PARP inhibitors.

bioRxiv · Jul 14, 2022 · PreprintCancer Biology

Unconstrained generation of synthetic antibody-antigen structures to guide machine learning methodology for real-world antibody specificity prediction

P. A. Robert, R. Akbar, R. Frank, M. Pavlovic, M. Widrich, I. Snapkov, A. Slabodkin, M. Chernigovskaya, L. Scheffer, E. Smorodina, P. Rawat, B. B. Mehta, M. H. Vu, I. Froberg Mathisen, A. Prosz, , V. Greiff

The paper introduces Absolut!, a software suite generating synthetic antibody-antigen structures to benchmark machine learning methods for antibody specificity prediction.

bioRxiv · Jul 6, 2021Immunology